2,46 Mb - GuíaSalud

199. Vijan S. Hypertension in diabetes. In: BMJ Publishing Group, editor. Clinical Evidence.
2006. p. 1-12.
200. Llisterri Caro JL, Rodriguez Roca GC, onso Moreno FJ, Lou AS, vison Garrote JA, Santos
Rodriguez JA, et al. Control de la presión arterial en la población hipertensa española atendida
en atención primaria. Estudio PRESCAP 2002. Med Clin (Barc). 2004;122(5):165-71.
201. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, et al. Clinical outcomes
in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration,
and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165(12):1401-9.
202. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results
of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in
patients with hypertension and NIDDM. Diabetes Care. 1998;21(4):597-603.
203. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect
of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with
non-insulin-dependent diabetes and hypertension. New England Journal of Medicine.
1998;338(10):645-52.
204. Mancia G, Brown M, Castaigne A, de LP, Palmer CR, Rosenthal T, et al. Outcomes with
nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention
as a Goal in Hypertension (INSIGHT). Hypertension. 2003;41(3):431-6.
205. Grossman E, Messerli FH. Are calcium antagonists beneficial in diabetic patients with hypertension?
Am J Med. 2004;116(1):44-9.
206. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular
morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint
reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet.
2002;359(9311):1004-10.
207. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Betablockers
for hypertension. Cochrane Database Syst Rev. 2007;(1):CD002003.
208. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland Schumacher H,
Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk
for vascular events. N engl J Med. 2008;358(15):1547-59.
209. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and
indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes
mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-40.
210. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes
mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes
Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253-9.
211. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, et al. Development
and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective
Diabetes Study (UKPDS 64). Kidney International. 2003;63(1):225-32.
212. Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney
disease. Cochrane Database Syst Rev. 2005;(4):CD004136.
213. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of
inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes:
systematic review and meta-analysis. The Lancet. 366(9502):2026-33.
174 CLINICAL PRACTICE GUIDELINES IN THE NHS